Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 1 patents
14 readers on Mendeley
  • Article usage
  • Citations to this article (110)

Advertisement

Free access | 10.1172/JCI108899

Absorption, Plasma Transport, and Cellular Retention of Cobalamin Analogues in the Rabbit: EVIDENCE FOR THE EXISTENCE OF MULTIPLE MECHANISMS THAT PREVENT THE ABSORPTION AND TISSUE DISSEMINATION OF NATURALLY OCCURRING COBALAMIN ANALOGUES

J. Fred Kolhouse and Robert H. Allen

Division of Hematology-Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110

Find articles by Kolhouse, J. in: PubMed | Google Scholar

Division of Hematology-Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110

Find articles by Allen, R. in: PubMed | Google Scholar

Published December 1, 1977 - More info

Published in Volume 60, Issue 6 on December 1, 1977
J Clin Invest. 1977;60(6):1381–1392. https://doi.org/10.1172/JCI108899.
© 1977 The American Society for Clinical Investigation
Published December 1, 1977 - Version history
View PDF
Abstract

Analogues of cobalamin (Cbl; vitamin B12) are prevalent in nature as a result of bacterial synthesis, and are of additional interest because of their potential use as antimetabolites and chemotherapeutic agents. We have synthesized 14 Cbl analogues containing 57Co and have compared their gastrointestinal absorption, plasma transport, and cellular retention to that of [58Co]Cbl in rabbits.

Many of the Cbl analogues were bound with low affinity by intrinsic factor, and none of these [57Co]Cbl analogues were taken up by the ileum or absorbed into the body in amounts comparable to that of [58Co]Cbl. The Cbl analogues that were bound by intrinsic factor with high affinity were taken up by the ileum but, in many cases, they were retained there in significant amounts.

Most of the Cbl analogues were bound by plasma transcobalamin II with high affinity and all of these transcobalamin II-[57Co]Cbl analogue complexes were taken up by a variety of tissues in a manner that was indistinguishable from that of transcobalamin II-[58Co]Cbl. The few analogues that were bound by transcobalamin II with low affinity were taken up by tissues in lesser amounts, and 20-70% of these analogues was rapidly excreted in the urine as occurs with native Cbl when it is present in plasma in unbound form.

All of the Cbl analogues were bound by the granulocyte R-type Cbl-binding protein with high affinity and all of the R-type protein-[57Co]Cbl analogue complexes were cleared rapidly from plasma exclusively by hepatocytes as occurs with R-type protein-[58Co]Cbl. Some Cbl analogues were released back into the plasma and were disseminated among a variety of tissues via transcobalamin II as occurs with native Cbl. Other Cbl analogues were retained in the liver and eventually excreted in the feces and urine without accumulating in other tissues.

These studies indicate that intrinsic factor and the ileum prevent certain Cbl analogues from entering the body and that the granulocyte R-type protein and hepatocytes prevent the dissemination of certain Cbl analogues that may gain entry such as during infections with Cbl analogue-producing bacteria. The fact that transcobalamin II binds and transports a large number of Cbl analogues indicates that these protective mechanisms can be circumvented and supports the feasibility of using Cbl analogues as antimetabolites in vivo.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1381
page 1381
icon of scanned page 1382
page 1382
icon of scanned page 1383
page 1383
icon of scanned page 1384
page 1384
icon of scanned page 1385
page 1385
icon of scanned page 1386
page 1386
icon of scanned page 1387
page 1387
icon of scanned page 1388
page 1388
icon of scanned page 1389
page 1389
icon of scanned page 1390
page 1390
icon of scanned page 1391
page 1391
icon of scanned page 1392
page 1392
Version history
  • Version 1 (December 1, 1977): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article (110)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
14 readers on Mendeley
See more details